We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Bioline Rx Ltd (BLRX) ADS EACH REPR 15 ORD SPON

Sell:$0.20 Buy:$0.21 Change: $0.001 (0.50%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$0.20
Buy:$0.21
Change: $0.001 (0.50%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$0.20
Buy:$0.21
Change: $0.001 (0.50%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Contact details

Address:
Modi'in Technology Park
2 HaMa'ayan Street
MODIIN
7177871
Israel
Telephone:
+972 (8) 6429100
Website:
https://www.biolinerx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BLRX
ISIN:
US09071M2052
Market cap:
$21.07 million
Shares in issue:
1.20 billion
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Aharon Schwartz
    Chairman of the Board
  • Philip Serlin
    Chief Executive Officer
  • Mali Zeevi
    Chief Financial Officer
  • Ella Sorani
    Vice President - Development
  • Abi Vainstein-Haras
    Vice President-Clinical & Medical Affairs
  • Hillit Mannor Shachar
    Vice President - Business Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.